Claims for Patent: 7,932,267

Summary for Patent: 7,932,267

Title:	Use of .alpha.-glucosidase inhibitors to treat alphavirus infections
Abstract:	The present invention provides methods for treating a flavivirus infection, including hepatitis C virus (HCV) infection, in an individual suffering from a flavivirus infection. In some embodiments, the methods involve administering to an individual in need thereof an effective amount of an agent that inhibits enzymatic activity of a membrane-bound .alpha.-glucosidase inhibitor. In other embodiments, the methods involve administering to an individual in need thereof effective amounts of an .alpha.-glucosidase inhibitor and at least one additional therapeutic agent.
Inventor(s):	Blatt; Lawrence M. (San Francisco, CA), Tan; Hua (Daly City, CA), Seiwert; Scott (Pacifica, CA)
Assignee:	Intermune, Inc. (Brisbane, CA)
Application Number:	12/617,676
Patent Claims:	1. A method of treating a flavivirus infection in an individual, the method comprising administering to an individual in need thereof an effective amount of an agent that inhibits enzymatic activity of a membrane-bound .alpha.-glucosidase, wherein the agent is miglitol. 2. The method of claim 1, wherein the agent inhibits the p7 protein of hepatitis C virus. 3. The method of claim 1 wherein the .alpha.-glucosidase inhibitor is administered at a dose of about 10 mg to about 30 mg per day. 4. The method of claim 1 wherein the .alpha.-glucosidase inhibitor is administered at a dose of about 30 mg to about 60 mg per day. 5. The method of claim 1 wherein the .alpha.-glucosidase inhibitor is administered at a dose of about 10 mg three times daily; about 15 mg three times daily; or about 20 mg three times daily. 6. A method of treating a flavivirus infection in an individual, the method comprising administering to an individual in need thereof effective amounts of an .alpha.-glucosidase inhibitor and an additional therapeutic agent, wherein the .alpha.-glucosidase inhibitor is miglitol, and wherein the additional therapeutic agent is selected from the group consisting of an interferon-.alpha. (IFN-.alpha.), an interferon-.gamma. (IFN-.gamma.), and a nucleoside analog. 7. The method of claim 6, wherein the IFN-.alpha. is interferon alfacon-1. 8. The method of claim 7, wherein the IFN-.alpha. is pegylated. 9. The method of claim 8, wherein the pegylated IFN-.alpha. is selected from peginterferon alfa-2a, peginterferon alfa-2b, and monoPEG (30 kD, linear)-ylated consensus IFN-.alpha.. 10. The method of claim 7, wherein the IFN-.alpha. is hyperglycosylated. 11. The method of claim 6, wherein the IFN-.gamma. is interferon gamma-1b. 12. The method of claim 11, wherein the IFN-.gamma. is pegylated. 13. The method of claim 11, wherein the IFN-.gamma. is hyperglycosylated. 14. The method of claim 6, wherein the nucleoside analog is selected from viramidine, ribavirin, and levovirin. 15. The method of any one of claims 1, 2, 6, 7-10, 11-13 or 14, wherein the individual is a human.

Details for Patent 7,932,267

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Kadmon Pharmaceuticals Llc	INFERGEN	interferon alfacon-1	Injection	103663	October 06, 1997	7,932,267	2029-11-12
Horizon Therapeutics Ireland Dac	ACTIMMUNE	interferon gamma-1b	Injection	103836	February 25, 1999	7,932,267	2029-11-12
Merck Sharp & Dohme Llc	PEGINTRON	peginterferon alfa-2b	Injection	103949	January 19, 2001	7,932,267	2029-11-12
Merck Sharp & Dohme Llc	SYLATRON	peginterferon alfa-2b	For Injection	103949	March 29, 2011	7,932,267	2029-11-12
Pharmaand Gmbh	PEGASYS	peginterferon alfa-2a	Injection	103964	October 16, 2002	7,932,267	2029-11-12
Pharmaand Gmbh	PEGASYS	peginterferon alfa-2a	Injection	103964	January 07, 2004	7,932,267	2029-11-12